PASADENA, Calif.--(BUSINESS WIRE)--Novelix Pharmaceuticals Inc. (Novelix), a biopharmaceutical company focused on the development of first in class small molecule cancer therapeutics, announced today that it has licensed its drug candidate NVX-207 to AOP Orphan Pharmaceuticals AG. The exclusive but restricted license will enable AOP Orphan Pharmaceuticals to develop and commercialize NVX-207 in human orphan designations in all territories outside the United States. Financial terms of the agreement were not disclosed.
